Mirati Therapeutics, Inc.
(NASDAQ : MRTX)

( )
MRTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.90%168.391.3%$496.78m
BIIBBiogen Inc.
0.65%230.761.3%$480.84m
CELGCelgene Corporation
-0.62%94.831.3%$471.13m
GILDGilead Sciences, Inc.
-0.75%65.860.9%$453.88m
ILMNIllumina, Inc.
-2.29%300.593.5%$305.96m
REGNRegeneron Pharmaceuticals, Inc.
-0.78%302.572.6%$276.84m
AAgilent Technologies, Inc.
-0.29%68.911.6%$198.64m
VRTXVertex Pharmaceuticals Incorporated
-1.78%165.731.9%$176.80m
EXASExact Sciences Corporation
-0.16%96.0425.3%$171.72m
ALXNAlexion Pharmaceuticals, Inc.
-2.80%127.232.0%$150.06m
BMRNBioMarin Pharmaceutical Inc.
-2.31%86.664.3%$118.53m
SRPTSarepta Therapeutics, Inc.
-3.37%117.5714.7%$114.20m
INCYIncyte Corporation
-0.48%76.832.5%$105.26m
IONSIonis Pharmaceuticals, Inc.
0.09%67.468.2%$98.12m
ALNYAlnylam Pharmaceuticals, Inc
-2.49%65.869.2%$93.34m

Company Profile

Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.